Praxis Precision Medicines Inc’s filing revealed that its General Counsel and Secretary Nemiroff Alex unloaded Company’s shares for reported $0.66 million on Nov 14 ’24. In the deal valued at $80.20 per share,8,239 shares were sold. As a result of this transaction, Nemiroff Alex now holds 10,301 shares worth roughly $ 0.81 million.
Then, Mastrocola Lauren sold 5,188 shares, generating $424,318 in total proceeds. Upon selling the shares at $81.78, the Principal Accounting Officer now owns 5,613 shares.
Before that, Mastrocola Lauren bought 5,189 shares. Praxis Precision Medicines Inc shares valued at $424,316 were divested by the Officer at a price of $81.77 per share.
Deutsche Bank initiated its Praxis Precision Medicines Inc [PRAX] rating to a Buy in a research note published on February 11, 2025; the price target was $111. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early August with a ‘”an Outperform”‘ rating. Needham began covering PRAX with “Buy” recommendation on June 24, 2024. Guggenheim started covering the stock on June 18, 2024. It rated PRAX as “a Buy”.
Price Performance Review of PRAX
On Tuesday, Praxis Precision Medicines Inc [NASDAQ:PRAX] saw its stock fall -13.35% to $78.65. Over the last five days, the stock has lost -7.31%. Praxis Precision Medicines Inc shares have risen nearly 2.20% since the year began. Nevertheless, the stocks have risen 85.98% over the past one year. While a 52-week high of $91.83 was reached on 02/14/25, a 52-week low of $33.01 was recorded on 01/13/25. SMA at 50 days reached $76.22, while 200 days put it at $61.66.
Levels Of Support And Resistance For PRAX Stock
The 24-hour chart illustrates a support level at 72.57, which if violated will result in even more drops to 66.48. On the upside, there is a resistance level at 88.17. A further resistance level may holdings at 97.68. The Relative Strength Index (RSI) on the 14-day chart is 47.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.25, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bearish at 71.90%. Stochastics %K at 72.20% indicates the stock is a holding.
The most recent change occurred on May 01, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $117 price target.
